Cargando…
Ayurvedic formulations: Potential COVID-19 therapeutics?
Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020642/ https://www.ncbi.nlm.nih.gov/pubmed/35474908 http://dx.doi.org/10.1016/j.phyplu.2022.100286 |
_version_ | 1784689596164997120 |
---|---|
author | Mahaboob Ali, Anees Ahmed Bugarcic, Andrea Naumovski, Nenad Ghildyal, Reena |
author_facet | Mahaboob Ali, Anees Ahmed Bugarcic, Andrea Naumovski, Nenad Ghildyal, Reena |
author_sort | Mahaboob Ali, Anees Ahmed |
collection | PubMed |
description | Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practitioners with minimal adverse reactions and intense research efforts are currently under way to develop some of these formulations for COVID-19 treatment. Methods: Literature search for in silico, in vitro, in vivo, and clinical studies on the topic of Ayurvedic formulations for potential COVID-19 treatment, in order to present the current state of current knowledge by integrating information across all systems. Results: The search yielded 20 peer reviewed articles on in silico studies examining the interaction of phytoconstituents of popular Ayurvedic formulations with SARS-CoV-2 components and its receptors; five articles on preclinical investigations of the ability of selected Ayurvedic formulations to inhibit functions of SARS-CoV-2 proteins; and 51 completed clinical trials on the efficacy of using Ayurvedic formulations for treatment of mild to moderate COVID-19. Clinical data was available from 17 of the 51 trials. There was a considerable overlap between formulations used in the in silico studies and the clinical trials. This finding was unexpected as there is no clearly stated alignment between studies and the traditional pathway to drug discovery– basic discovery leading to in vitro and in vivo proof of concept, followed by validation in clinical trials. This was further demonstrated in the majority of the in silico studies where focus was on potential antiviral mechanisms, while the clinical trials were focused on patient recovery using oral treatments. In all 17 clinical trials where data was available, Ayurvedic treatments lead to a shorter period to recovery in participants with COVID-19. Conclusion: The most commonly used Ayurvedic treatments for management of respiratory symptoms associated with SARS-CoV-2 infection appear to have prophylactic and/or therapeutic properties. It would be of particular interest to assess synergistic and concomitant systemic effects and antiviral activities of individual phytoconstituents and their combinations in the Ayurvedic treatments. |
format | Online Article Text |
id | pubmed-9020642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90206422022-04-21 Ayurvedic formulations: Potential COVID-19 therapeutics? Mahaboob Ali, Anees Ahmed Bugarcic, Andrea Naumovski, Nenad Ghildyal, Reena Phytomed Plus Article Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practitioners with minimal adverse reactions and intense research efforts are currently under way to develop some of these formulations for COVID-19 treatment. Methods: Literature search for in silico, in vitro, in vivo, and clinical studies on the topic of Ayurvedic formulations for potential COVID-19 treatment, in order to present the current state of current knowledge by integrating information across all systems. Results: The search yielded 20 peer reviewed articles on in silico studies examining the interaction of phytoconstituents of popular Ayurvedic formulations with SARS-CoV-2 components and its receptors; five articles on preclinical investigations of the ability of selected Ayurvedic formulations to inhibit functions of SARS-CoV-2 proteins; and 51 completed clinical trials on the efficacy of using Ayurvedic formulations for treatment of mild to moderate COVID-19. Clinical data was available from 17 of the 51 trials. There was a considerable overlap between formulations used in the in silico studies and the clinical trials. This finding was unexpected as there is no clearly stated alignment between studies and the traditional pathway to drug discovery– basic discovery leading to in vitro and in vivo proof of concept, followed by validation in clinical trials. This was further demonstrated in the majority of the in silico studies where focus was on potential antiviral mechanisms, while the clinical trials were focused on patient recovery using oral treatments. In all 17 clinical trials where data was available, Ayurvedic treatments lead to a shorter period to recovery in participants with COVID-19. Conclusion: The most commonly used Ayurvedic treatments for management of respiratory symptoms associated with SARS-CoV-2 infection appear to have prophylactic and/or therapeutic properties. It would be of particular interest to assess synergistic and concomitant systemic effects and antiviral activities of individual phytoconstituents and their combinations in the Ayurvedic treatments. The Author(s). Published by Elsevier B.V. 2022-08 2022-04-20 /pmc/articles/PMC9020642/ /pubmed/35474908 http://dx.doi.org/10.1016/j.phyplu.2022.100286 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Mahaboob Ali, Anees Ahmed Bugarcic, Andrea Naumovski, Nenad Ghildyal, Reena Ayurvedic formulations: Potential COVID-19 therapeutics? |
title | Ayurvedic formulations: Potential COVID-19 therapeutics? |
title_full | Ayurvedic formulations: Potential COVID-19 therapeutics? |
title_fullStr | Ayurvedic formulations: Potential COVID-19 therapeutics? |
title_full_unstemmed | Ayurvedic formulations: Potential COVID-19 therapeutics? |
title_short | Ayurvedic formulations: Potential COVID-19 therapeutics? |
title_sort | ayurvedic formulations: potential covid-19 therapeutics? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020642/ https://www.ncbi.nlm.nih.gov/pubmed/35474908 http://dx.doi.org/10.1016/j.phyplu.2022.100286 |
work_keys_str_mv | AT mahaboobalianeesahmed ayurvedicformulationspotentialcovid19therapeutics AT bugarcicandrea ayurvedicformulationspotentialcovid19therapeutics AT naumovskinenad ayurvedicformulationspotentialcovid19therapeutics AT ghildyalreena ayurvedicformulationspotentialcovid19therapeutics |